Spero Therapeutics, Inc.
SPRO
$2.64
-$0.14-5.04%
NASDAQ
| 12/31/2025 | 09/30/2025 | 06/30/2025 | 03/31/2025 | 12/31/2024 | |
|---|---|---|---|---|---|
| Revenue | 174.51% | -59.60% | 39.15% | -36.61% | -79.54% |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 174.51% | -59.60% | 39.15% | -36.61% | -79.54% |
| Cost of Revenue | -194.61% | -68.00% | -55.02% | -21.50% | -41.67% |
| Gross Profit | 896.67% | 76.45% | 126.00% | 4.13% | -157.26% |
| SG&A Expenses | -39.06% | -19.70% | 6.24% | 15.33% | 9.68% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | -72.44% | -60.17% | -43.43% | -12.13% | 56.12% |
| Operating Income | 250.64% | 60.58% | 87.61% | -4.11% | -141.26% |
| Income Before Tax | 254.29% | 57.66% | 90.48% | -9.45% | -139.94% |
| Income Tax Expenses | -10.00% | -- | -- | -- | -25.06% |
| Earnings from Continuing Operations | 250.90% | 56.95% | 90.48% | -9.45% | -140.80% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | 250.90% | 56.95% | 90.48% | -9.45% | -140.80% |
| EBIT | 250.64% | 60.58% | 87.61% | -4.11% | -141.26% |
| EBITDA | 250.64% | 60.58% | 87.62% | -4.79% | -141.23% |
| EPS Basic | 246.92% | 58.59% | 90.85% | -5.79% | -139.65% |
| Normalized Basic EPS | 256.90% | 62.51% | 91.30% | -4.46% | -137.16% |
| EPS Diluted | 239.47% | 58.59% | 90.85% | -5.79% | -139.87% |
| Normalized Diluted EPS | 248.05% | 62.51% | 91.30% | -4.46% | -137.23% |
| Average Basic Shares Outstanding | 2.72% | 3.98% | 3.83% | 3.46% | 2.90% |
| Average Diluted Shares Outstanding | 8.86% | 3.98% | 3.83% | 3.46% | 2.69% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |